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ABSTRACT 
Background. HLA and IL28B genes were independently associated with severity of 
HCV-related liver disease. We investigated the effects of these combined genetic 
factors on post-transplant survival in HCV-infected recipients, aiming to provide new 
data to define the optimal timing of novel antiviral therapies in the transplant setting. 
Methods. HLA-A/B/DRB1 alleles and IL28B rs12979860 (C>T) polymorphism 
frequencies were determined in 449 HCV viremic recipients and in their donors. 
Median follow-up was ten years; study outcome was graft survival. 
Results. HLA-DRB1*11 phenotype and IL28B C/C genotype were significantly less 
frequent in recipients than donors (27.8% vs. 45.9% and 27.4% vs. 44.9%, 
respectively, p<0.00001). Ten-year graft survival was better in patients with HLA-
DRB1*11 (p=0.0183) or IL28B C/C (p=0.0436). Conversely, concomitant absence of 
HLA-DRB1*11 and IL28B C/C in 228 (50.8%) predicted worse survival (p=0.0006), 
which was already evident at the first post-transplant year (p=0.0370). In 
multivariable Cox analysis, absence of both markers ranked second as risk factor for 
survival (HR=1.74), following donor age ≥70 years (HR=1.77). 
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Conclusions. In the current era of direct-acting antiviral agents, the negative effects 
of this common immunogenetic profile in HCV-infected recipients could be most 
effectively neutralized by peri-transplant treatment. This should be particularly 
relevant in countries where elderly donors represent an unavoidable resource. 
 
INTRODUCTION 
Hepatitis C virus (HCV) infects approximately 1.6% of the world's population [1], and 
HCV cirrhosis is the leading indication for liver transplantation (LT) in adults [2]. In 
recipients with viremia at LT, HCV recurrence is universal [3] and survival is reduced. 
Progression of liver disease is accelerated after LT, with chronic hepatitis developing 
in 50-90% of patients by 12 months and bridging fibrosis/cirrhosis in 20-54% by 5 
years after LT [4]. Recurrent HCV is the main cause of graft failure and patient death 
in HCV-infected recipients [5], and treatment achieving viral eradication before or 
after LT would improve patient and graft survival [6] . 
 
High viral load, genotype 1 virus, female gender, older donor age, treated 
cytomegalovirus (CMV) infection and acute rejection were associated with an 
increased risk of severe recurrent hepatitis C [6]. 
 
Host immune responses may be crucial in determining the fate of the graft in the 
context of alloimmunity and immunosuppression. Several studies have correlated the 
expression of human leukocyte antigen (HLA) variants with spontaneous viral 
clearance or evolution of liver disease in the non-transplant setting, but only a few 
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evaluated the association of HLA with severity of HCV disease after transplant [7,8]. 
Single nucleotide polymorphisms (SNP) upstream of the Interleukin 28B (IL28B) 
gene encoding interferon lambda-3 (IFN-λ-3), were shown to influence the outcome 
of HCV infection, and the rs12979860 C/C genotype was found to be protective both 
in the immunocompetent [9,10] and in the immunosuppressed host [11-13]. 
However, no study addressed the impact of the combination of these two 
immunogenetic factors on the outcome of LT in HCV recipients. 
 
Interferon and ribavirin were poorly tolerated in transplant candidates while, even if 
initiated at an early stage of recurrent hepatitis C post-LT, they achieved sustained 
virological response (SVR) rates around 30% [6,14,15]. The addition of first 
generation protease inhibitors improved SVR rates to 50-60% [16], however, side 
effects and drug-drug interactions make this therapy cumbersome [17]. The recent 
advent of new direct-acting antiviral agents (DAAs) is revolutionizing anti-HCV 
therapies towards pan-genotypic, interferon-free regimens [18]. In patients with 
compensated cirrhosis results are similar to patients without cirrhosis [19], and the 
associations sofosbuvir-ledipasvir and sofosbuvir-daclatasvir are available also for 
Child class B and C patients, although severity of liver disease influences response 
rates (around 80% compared to 95% for Child A) [20,21]. Therefore, new 
management paradigms are emerging in the transplant field: to pursue viral 
eradication before LT (to improve or stabilize liver function in listed patients and to 
avoid graft infection) [22] or as early as possible after LT (pre-emptive therapy to 
prevent inflammation and fibrosis in the transplanted liver), rather than waiting for 
hepatitis C recurrence before starting treatment. However, unpredictable waiting 
time, risk of patient death and/or tumor progression on the list, occurrence of delayed 
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graft function after LT or of severe kidney impairment both before and after 
transplant, and the new dilemmas about using HCV-positive donors are fuelling the 
debate on the best timing for HCV therapy [23-27]. 
 
In this study on HCV patients managed in the interferon era, we investigated the 
effects of the recipient immunogenetic make-up on post-transplant graft survival, 
aiming to provide new data helpful to define the optimal timing to start novel antivirals 
in the transplant setting. 
 
MATERIALS AND METHODS 
Study population 
This retrospective study is based on 1,506 consecutive orthotopic LTs performed at 
the Turin Liver Transplant Center from January 1999 to December 2009. The time 
span was chosen to obtain long-term follow-up data before the introduction of new 
antivirals against the HCV. Excluded from the study were 86 pediatric, 11 living-
related, 8 dominoes and 125 re-transplants as well as 27 primary transplants for 
which a recipient DNA sample was not available. 
 
Within the remaining 1,249 adult primary LT recipients, 738 were anti-HCV antibody 
negative and 511 anti-HCV antibody positive; the latter underwent HCV RNA plasma 
level and genotype determination as part of their pre-transplant work-up. The donors 
were similarly studied for HCV in blood collected during the brain death observation 
period. 
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Twenty-one anti-HCV positive but HCV RNA negative recipients and 41 anti-HCV 
positive patients who received the graft from an anti-HCV positive donor were not 
considered. 
 
Ultimately, 449 HCV viremic recipients of grafts from HCV-negative brain-dead heart-
beating donors, represent the study population (Figure 1).  
 
The recipient and donor features of 449 HCV and 738 non-HCV transplants are 
shown in Supplementary Table 1. 
 
Informed consent was signed by all patients upon entering the waiting list. Due to the 
retrospective design, no specific approval was sought from the local Institutional 
Review Board; by Italian law, Regional Transplantation Centers are custodians of 
donor/recipient biomedical data also for research purposes. All study procedures 
complied with the ethical standards of the 2000 Declaration of Helsinki as well as the 
Declaration of Istanbul 2008. 
 
HCV testing 
Antibodies to HCV were detected in recipient and donor sera by the Architect assay, 
Abbott Laboratories, Abbott Park, IL, US. 
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Between January 1999 and April 2007 HCV RNA detection and quantitation were 
performed with a qualitative and quantitative assay. Qualitative detection was 
obtained by COBAS Amplicor® HCV system (Roche Molecular Systems Inc, 
Branchburg, NJ, US) with a detection limit of 50 IU/mL. Quantitative detection was 
performed by signal amplification Branched-DNA test (Versant® HCV version 3.0, 
Bayer Diagnostic Corporation, Tarrytown, NY, US) with a dynamic range of 
quantitation from 615 to 7.7 x 106 IU/mL. After April 2007, plasma HCV RNA was 
detected and quantified by the automated high-sensitivity system COBAS 
AmpliPrep®/COBAS TaqMan® HCV Version 1 (Roche Molecular Systems Inc). The 
dynamic range of quantitation went from 43 to 6.9 x 107 IU/mL. After October 2012, 
the Version 2 of the AmpliPrep®/COBAS TaqMan® HCV test was introduced, with a 
dynamic range of quantitation from 15 to 1 x 108 IU/mL. 
 
HCV genotypes were determined with a reverse hybridization line probe assay 
(INNO-LIPA, Innogenetics, Ghent, Belgium) after nested-polymerase chain reaction 
amplification of the 5’NC viral region. 
HLA typing 
Recipient and donor peripheral blood was prospectively collected in ethylene-
diamine-tetra-acetic acid, and genomic DNA was banked after extraction by ‘salting 
out’ method or automatically (Macherey-Nagel GmbH, Düren, Germany). HLA loci A 
and B were typed by serology, while HLA-DRB1 was typed by serology until 2006 
and then by molecular low-resolution with sequence-specific primer technology. A 
sample of recipients and donors was also typed at high resolution by sequence-
specific primer technology to detect HLA-DRB1*11 subtypes. 
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IL28B SNP typing 
We investigated the IL28B rs12979860 (C>T) polymorphism using the biorepository 
of recipient and donor DNAs of our Immunogenetics Laboratory. The Custom 
TaqMan® Allelic Discrimination Kit (Life Technologies Applied Biosystems®, Thermo 
Fisher Scientific, Waltham, MA, US) was used for the allelic discrimination of the 
selected SNP. Upstream and downstream primers (Forward: 
GCCTGTCGTGTACTGAACCA; Reverse: GCGCGGAGTGCAATTCAAC) and two 
TaqMan® probes (5'-VIC-TGGTTCGCGCCTTC-3' and 5'-FAM-
CTGGTTCACGCCTTC-3') were used, one probe for each allele in a two-allele 
system. The TaqMan® method was carried out with Applied Biosystems® 7500 Real-
Time PCR Systems (Thermo Fisher Scientific). 
 
Clinical protocol 
Immunosuppression was based on calcineurin inhibitors (mainly cyclosporine), 
antimetabolites and steroids (tapered to suspension in 6 months). Moderate or 
severe acute rejection episodes were treated with high-dose methylprednisolone 
boluses on three consecutive days; monoclonal anti-CD3 antibodies were used in 
steroid-resistant rejections. 
 
Follow-up liver biopsies were performed as dictated by clinical needs. Recurrent 
hepatitis C was graded and staged by Ishak score [28]. 
Therapy against recurrent HCV infection was based on ribavirin and interferon-α or 
peginterferon-α given for 12 months or according to tolerance. No patient was 
treated while on the waiting list. Criteria for HCV treatment after LT were absence of 
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contraindications (mainly neutropenia, anemia, thrombocytopenia, renal failure, 
biliary complication, psychiatric disorders), a minimum 3-months interval from LT and 
mild to moderate fibrosis (score ≥ 2/6 Ishak) or evidence of fibrosing cholestatic 
hepatitis. 
The variables assessed in the study population are shown in Table 3. 
 
Study outcome 
Graft survival was the sole study outcome; patient survival would have been biased 
by factors influencing the decision whether to retransplant or not a patient with a 
failing graft in the setting of recurrent HCV disease.  
Survival data were collected up to June 30, 2014, because starting from July 2014 
new direct anti-HCV agents became available in our Center. Any surviving patient 
with the original graft was censored, while graft losses and their causes were 
recorded at the time of patient death or retransplantation.  
Survival results obtained in the 738 non-HCV recipients were compared with the 
HCV-infected study population.  
 
Statistical analysis 
Allelic, phenotypic and genotypic frequencies were assessed by direct counting. 
HLA-A,-B,-DRB1 phenotypic frequencies and all other categorical variables were 
compared by n x m cells chi-square test and Bonferroni post-hoc correction for 
multiple comparisons. A p value < 0.05 was otherwise considered statistically 
significant.  
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Results for ordinal variables are expressed as mean ± standard deviation or as 
median and interquartile range, as appropriate. A two-tailed t-test was adopted to 
compare differences between normally distributed variables (normality assessed by 
Kolmogorov-Smirnov test). Differences between not normally distributed variables 
were assessed by the Mann-Whitney U test.  
 
To evaluate the effect of individual categorical variables on graft survival, Kaplan-
Meier analysis was employed and survival curves were compared using the log-rank 
test. Then, a Cox regression model was used to analyze the one-year graft survival 
with artificial censoring of all graft losses after one year; short-term hazard ratios 
(HR), 95% confidence intervals and p values were thus calculated.  
 
To obtain a parsimonious set of pre-transplant predictors of graft survival, recipient 
and donor variables were selected based on the background knowledge (6), 
irrespective of their performance at univariate analysis. They were fitted 
simultaneously into a multivariable Cox proportional hazards regression model and a 
backward selection method was used. In the backward elimination the results of the 
Wald test for individual variables were examined and the least significant parameter 
that did not meet the level for staying in the model (set at p-value = 0.157, 
corresponding to selection by Akaike’s information criterion), was removed.  
 
Finally, we checked for interactions by including variables in the model as well as 
their cross-product and by testing the statistical significance of the cross-product 
term.  
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Data were analyzed by StatSoft STATISTICA software package Version 8.0 and IBM 
SPSS Version 21. 
 
RESULTS 
1. Comparison of immunogenetic markers 
1.1 HLA frequencies 
Table 1 shows the statistically significant differences in HLA phenotypic frequencies 
between the 449 HCV-infected recipients and their HCV-negative donors, the 
complete pattern of HLA frequencies being depicted in Supplementary Table 2. 
Comparing recipients with donors, HLA-B*13 and HLA-B*16 were significantly less 
frequent in donors, while HLA-DRB1*11 was significantly less frequent in recipients. 
In the latter, the frequencies of the other HLA-DRB1 antigens, especially HLA-
DRB1*7, were proportionately increased.  
The relative frequencies of the most common HLA-DRB1*11 subtypes (DRB1*11:01, 
*11:02, *11:03, *11:04) were examined in a sample of HLA-DRB1*11-positive 
recipients and donors. No differences were found, and they were in line with those of 
the Italian population (Supplementary Table 3). 
 
1.2 IL28B SNP frequencies  
As shown in Table 2, C allele and C/C genotype were significantly less frequent in 
HCV-infected recipients than in their HCV-negative donors, and allelic/genotypic 
frequencies showed Hardy-Weinberg equilibrium in the donors, but not in the 
recipients (p=0.0039). 
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The frequency of C/C genotype was significantly higher in donors aged 70 years or 
more (Supplementary Table 4), and C/C donors were older than non-C/C ones 
(median age: 63 vs. 58 years, p=0.0286). 
 
2. Graft survival after LT 
The median follow-up for surviving grafts was 10 years (range 4.5 to 15.5). 
The ten-year graft survival rate was significantly lower in the 449 HCV than in the 
738 non-HCV recipients (p<0.00001). The two survival curves started to diverge few 
months after LT and the gap widened progressively over time (Supplementary 
Figure 1). 
Within the HCV patients, the HLA-DRB1*11-positive recipients had a graft survival 
significantly longer than the HLA-DRB1*11-negative ones, with a difference of 17% 
at ten years (p=0.0183) (Figure 2, Panel A). The recipient status for HLA-DRB1*7, 
HLA-B*13 and HLA-B*16 (Supplementary Figure 2) as well as the full 
donor/recipient mismatch at the DRB1 locus (Supplementary Figure 3) did not 
affect the outcome. 
The graft survival of HCV recipients was influenced also by the IL28B genotype of 
both the recipient and the donor, results being better in C/C recipients (p=0.0436) 
(Figure 2, Panel B) and with non-C/C donors (p=0.0257) (Supplementary Figure 
4). Looking at donor/recipient match for IL28B, the outcome was significantly worse 
in non-C/C recipients transplanted with a C/C donor (p=0.0240) (Supplementary 
Figure 5). 
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While the contemporary presence of HLA-DRB1*11 phenotype and IL28B C/C 
genotype in HCV recipients did not improve survival (Supplementary Figure 6), the 
absence of both variants predicted significantly worse LT results (p=0.0006) (Figure 
3, Panel A). The subdivision of HCV recipients in two groups according to the 
combination of these markers (HLA-DRB1*11-negative and IL28B non-C/C, n=228, 
50.8% vs. all other genetic combinations, n=221, 49.2%), demonstrated markedly 
different outcomes. Compared with the HCV recipients exhibiting all other genetic 
combinations, the patients lacking both these markers experienced a significant 
survival disadvantage as early as the first post-transplant year (p=0.0370), the one-
year risk of graft loss being increased by 68% (HR=1.68 [95% confidence interval: 
1.026-2.761], p=0.0390). In contrast, the one-year survival rate of HCV recipients 
with all other genetic combinations was equivalent to that of non-HCV ones (89% vs. 
90%, p=0.6232) (Figure 3, Panel B).  
 
In the two groups of HCV recipients, graft survival at one and ten years remained 
significantly different also when SVR patients were censored at the beginning of 
interferon-based therapy (Supplementary Figure 7, Panel A and B).   
 
Table 3 summarizes demographics and LT details of HCV patients divided according 
to their immunogenetic markers. While they did not differ for gender, Model for End-
stage Liver Disease (MELD) score, donor age and donor IL28B genotype, the 
recipients lacking both HLA-DRB1*11 and IL28B C/C showed: i) significantly higher 
HCV RNA levels before and 3 months after LT; ii) higher prevalences of genotype 1 
virus, HLA-DRB1 donor/recipient full mismatch, IL28B C/C donor to non-C/C 
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recipient, positive crossmatch, treated acute rejection, and treated CMV infection; iii) 
lower SVR rate to interferon therapy. 
 
Comparing causes of graft loss recorded by attending physicians at the time of the 
event, severe recurrent hepatitis C was more frequent (31.6% vs. 20.3%, p<0.0001) 
and twofold increased in both the short (< 1 year: 6.1% vs. 2.7%) and long term (> 5 
years: 12.3% vs. 6.3%) in HLA-DRB1*11-negative and IL28B non-C/C recipients, 
while the rates of graft loss due to recurrent hepatocellular carcinoma (HCC) or not 
primarily attributed to HCV recurrence were not significantly different between the 
two groups (Supplementary Table 5). 
Lastly, the relevance of donor features was analyzed in the HCV recipients lacking 
both HLA-DRB1*11 and IL28B C/C. Regarding donor immunogenetic profile, 
receiving a graft from an HLA-DRB1*11-positive donor did not exert an appreciable 
protective effect, while a trend towards a worse graft survival was detected with 
IL28B C/C donors (Supplementary Table 6). It is worth noting that the C/C genotype 
was significantly more frequent in donors aged 70 years or more compared with 
younger than 70 (34/61, 55.7% vs. 63/164, 38.4%; p=0.0197). Focusing on donor 
age, survival rates markedly decreased with donors aged 70 years or more (the 
upper quartile in our study), being 71% at one year, 44% at five years and 29% at 
ten years (Figure 4, Panel A). With older donors, the survival disadvantage was 
already evident from the very first months after transplant, adding up to a difference 
of 15% at one year compared with recipients of a donor younger than 70 (p=0.0095), 
the one-year risk of graft loss being increased by more than 120% (HR=2.23 [95% 
confidence interval: 1.210-4.111], p=0.0100) (Figure 4, Panel B). 
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3. Multivariable analysis 
Table 4 summarizes the results of a backward selection multivariable analysis (Cox 
model) performed on a set of covariables with potential impact on graft survival 
(donor age, body mass index, anti-core HBV antibodies status, IL28B genotype; 
recipient age, gender, MELD score, HCV genotype, HCV RNA level, combined HLA-
DRB1*11/IL28B profile; crossmatch). The independent pre-transplant variables 
significantly affecting the outcome of LT in HCV recipients were: donor age ≥ 70 
years (HR=1.77), recipient lacking both HLA-DRB1*11 phenotype and IL28B C/C 
genotype (HR=1.74), MELD score ≥ 25 (HR=1.74), HCV RNA level before LT ≥ 1 x 
106 IU/mL (the median viremia level in the study population) (HR=1.45), and donor 
with IL28B C/C genotype (HR=1.45). 
 
Checking interaction, no synergy was found between HLA-DRB1*11 phenotype and 
IL28B genotype (p=0.886; HR=1.05; 95% confidence interval: 0.522-2.121).  
 
DISCUSSION 
In this study on primary transplants performed for HCV cirrhosis in the interferon era, 
we found that the combination of HLA-DRB1 and IL28B recipient markers identifies a 
large population of patients at increased risk of liver graft loss from the early post-
transplant period.  
 
Both innate and adaptive immunity play a role in HCV infection, leading to virus 
elimination in 20-30% of the patients during the acute phase [29,30]. Presentation of 
viral peptides to CD4 T-cells occurs preferentially in the context of specific HLA-
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class-II antigens and several studies demonstrated a protective role for HLA-
DRB1*11 in HCV infection [7,31]. HLA-DRB1*11 is less prevalent among HCV 
patients undergoing LT compared with healthy controls, and a fully mismatched 
donor/recipient pair at the DRB1 locus is associated with an increased severity of 
recurrent hepatitis C [8]. On the innate arm of the immune response, the IL28B gene 
product IFN-λ-3 is induced by viral infections and is up-regulated in hepatocytes and 
peripheral blood mononuclear cells of individuals with HCV infection [32]. IFN-λ-3 
enhances cellular immunity and it may be the main inducer of infection suppressor 
genes following HCV infection [33]. IL28B SNP rs12979860 affects expression of 
IFN-λ-3, with higher levels of IFN-λ-3 and a higher rate of spontaneous clearance of 
HCV in patients presenting a C/C genotype [10]. HCV-infected LT recipients with an 
IL28B genotype different from C/C (i.e. C/T or T/T) have been shown to suffer from 
earlier HCV recurrence and more severe fibrosis progression; on the contrary, the 
IL28B C/C genotype in the donor was associated with an adverse outcome in the 
recipient. Finally, an IL28B C/C genotype both in the recipient and in the donor was 
found to favor the response to interferon-based therapies [11-13].  
 
In our study we confirmed that in HCV recipients HLA-DRB1*11 is uncommon, and 
the frequency of other HLA-DRB1 alleles is increased; similarly, the frequencies of 
IL28B C allele and C/C genotype are reduced.  
 
Even if in HCV transplants a full mismatch at the HLA-DRB1 locus was shown to be 
associated with severity of hepatitis C recurrence [8], we failed to detect an impact of 
this donor/recipient combination on graft survival. Conversely, we were able to 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
extend from fibrosis progression to graft survival the findings of Duarte-Rojo [12] 
about the detrimental effect of the IL28B mismatch represented by C/C donor to non-
C/C recipient. 
 
Focusing on the recipient side, we found a significantly longer survival for HCV 
patients carrying either HLA-DRB1*11 phenotype or IL28B C/C genotype, 
independently from the donor’s genetic features. More importantly, we identified in 
half of our HCV recipients an immunogenetic profile (i.e. concurrent absence of both 
HLA-DRB1*11 and IL28B C/C) which predicted a much worse outcome starting from 
the first months post-transplant. These ‘at risk’ subjects did not differ from their 
‘protected’ counterparts for other characteristics which are known to affect LT results 
such as: recipient age, gender, liver disease severity, hepatocellular carcinoma; 
donor age, IL28B genotype, hepatitis B-core antibody positivity; graft macrovesicular 
steatosis, cold ischemic time; donor age times recipient’s MELD (D-MELD) [6,12,34]. 
On the other hand, they were more often infected with genotype 1 virus, viremia was 
significantly higher before and three months after LT, and SVR with interferon-based 
therapies was less frequent, in accordance with the knowledge that the IL28B C/C 
genotype is a robust predictor of response to interferon [9] and that non-C/C 
recipients show higher viral loads at hepatitis C recurrence after LT [12]. These data 
indicate that ‘at risk’ subjects are less resistant to the HCV both before and after LT.  
 
The immunological risk in these disadvantaged patients was further compounded by 
the higher prevalence of HLA-DRB1 donor/recipient full mismatch due to the marked 
phenotypic prevalence of the HLA-DRB1*11 in the general population [8,35], the 
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same selection bias possibly explaining also the higher prevalence of crossmatch 
positivity. In the ‘at risk’ recipients, alloimmunity may have increased the occurrence 
of acute rejection requiring treatment, with consequent weakening of immune 
defenses and increase of both CMV reactivations and HCV viremic levels 3 months 
after LT. It is a reasonable inference that this chain of events may favor a more 
severe course of HCV recurrence, with rapid and progressive injury leading to a 
higher rate of graft loss starting early after LT. 
 
Though its retrospective nature may be a limit of this study, a high number of patients 
were consecutively recruited at a single center. They were referred from all parts of 
Italy, therefore they are representative of an European, mainly Caucasian, 
population. Secondly, in our Center protocol biopsies are not envisaged, and liver 
elasticity studies were not available in the initial follow-up years; thus no data are 
available on the role of HLA-DRB1*11 and IL28B on fibrosis progression [36]. To 
offset this disadvantage, graft survival from the time of transplant was selected as a 
more robust outcome than disease evolution.  
 
The recent advent of new highly effective and safe antivirals is providing the mean to 
eradicate the HCV also in the transplant setting [37]. In the current transition phase 
in which many HCV candidates are still viremic when accessing to LT waiting lists, 
pre-transplant DAA-based treatment has been advocated as the most likely to reap 
most benefits [23]. Other Authors plead, instead, for a more selective use of DAAs in 
wait-listed patients [25] and suggest to delay HCV therapy after LT in most recipients 
until their clinical course has stabilized [38] or recurrent hepatitis C has been 
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histologically recognized, because solid data on pre-emptive therapy are still lacking 
(Belli LS, Oral Presentation at the Specialty Update Symposium ELITA – Advances 
and challenges of liver transplantation for HCV liver cirrhosis – ESOT Congress, 
Brussels, Belgium, September 13, 2015). Unfortunately, immediately after transplant, 
distinction between acute rejection and early recurrent hepatitis C [39] as well as 
between biliary obstruction and fibrosing cholestatic hepatitis C [40] remain 
challenging histological and clinical problems. Furthermore, HCV-infected transplant 
patients presenting early organ preservation injury, which is more marked in elderly 
grafts, show the poorest survival outcomes [41].  
 
In this complex scenario, while waiting for universal hepatitis C eradication before 
listing, the pre-LT typing of HLA-DRB1 and IL28B helps identifying HCV viremic 
recipients who are at an increased risk of graft loss starting from the first months 
after LT. Therefore, our study findings provide a new useful, low-cost decisional 
element for the timing of DAA-based therapy in the transplant setting, and suggest 
that immunogenetically ‘at risk’ patients are high priority candidates for pre-transplant 
or immediately post-transplant pre-emptive treatment [42,43]. This indication should 
be all the more relevant in high MELD candidates and in countries where elderly 
donors represent an unavoidable resource [44,45]. Conversely, immunogenetically 
‘low risk’ patients with viremia at LT could undergo antiviral therapy beyond 3 months 
following LT, when their clinical course has stabilized and early mortality risk has 
been overcome. 
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TABLE 1. Significant differences in HLA phenotypic frequencies between 
recipients and donors in HCV liver transplants 
HLA alleles 
HCV-positive recipients
(n=449) 
HCV-negative donors 
 (n=449) 
p value 
HLA-DRB1*11 125 (27.8%) 206 (45.9%) <0.00001
HLA-DRB1*7 163 (36.3%) 112 (24.9%) 0.0002 
HLA-B*13 58 (13.2%)# 31 (6.9%) 0.0018 
HLA-B*16 52 (11.8%)# 21 (4.7%) 0.0001 
In bold significant p values after Bonferroni correction (locus DRB1 <0.0042; locus B <0.0019) 
#8 missing data 
Abbreviations: HCV, hepatitis C virus; HLA, human leukocyte antigen 
 
 
TABLE 2. Allelic and genotypic frequencies of IL28B rs12979860 in HCV liver 
transplants 
IL28B alleles 
HCV-positive recipients
(n=449) 
HCV-negative donors 
(n=443)# p value 
C 498 (55.5%) 591 (66.7%) 
<0.00001 
T 400 (44.5%) 295 (33.3%) 
IL28B genotypes 
  
C/C 123 (27.4%) 199 (44.9%) <0.00001
C/T 252 (56.1%) 193 (43.6%) 0.0002
T/T 74 (16.5%) 51 (11.5%) 0.0326
In bold significant p values 
#6 missing data 
Abbreviations: HCV, hepatitis C virus; IL28B, Interleukin 28B 
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TABLE 3. Demographic and clinical characteristics of HCV liver transplant 
recipients divided in two groups according to their immunogenetic 
markers 
 
HLA-DRB1*11-
negative and IL28B 
non-C/C 
(n=228) 
All other genetic 
combinations 
(n=221) 
p value 
Recipient features    
Age (years) 56 [48-60]  55 [51-59]  0.9061 
Male 184 (80.7%) 179 (81%) 0.9370 
MELD at LT 15 [12-20] 15 [12-18] 0.4422 
HCC 96 (42.1%) 102 (46.2%) 0.3877 
HCV RNA before LT (log10 IU/mL) 6.14 [5.61-6.49] 5.92 [5.30-6.43] 0.0324 
Viral genotype  1/2/3/4£ 167(75.6%)/21/15/18 137(66.8%)/36/28/4 0.0002 
PRA Max  0-9/10-50/51-80/>80%$ 198/6/13/3 203/1/9/1 0.1525 
Waiting list time (months) 2.6 [1.5-4.5] 3.0 [1.3-5.2] 0.3275 
Donor features    
Age (years) 61 [49-71] 58 [47-69] 0.4154 
Male 126 (55.3%) 131 (59.3%) 0.3902 
HBV-core Ab positive donor 37 (16.2%) 36 (16.3%) 0.9859 
Body mass index 25 [23-27] 25 [23-28] 0.9840 
Macrovesicular steatosis  <15% / 
≥15%& 
167/22 154/25 
0.5040 
Graft quality   optimal/suboptimal& 83/106 84/95 0.5619 
HLA-DRB1*11-positive phenotype 103 (45.2%) 103 (46.6%) 0.7610 
IL28B genotype  C/C vs. non-C/C° 97(43.1%)/128 102(46.8%)/116 0.4366 
Split liver graft 7 (3.1%) 7 (3.2%) 0.6145 
Cold ischemic time (minutes) 500 ± 133 496 ± 142 0.7444 
Donor / Recipient match    
D-MELD 899 [619-1166] 845 [598-1152] 0.4052 
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IL28B C/C D to non-C/C R   yes/no° 97(43.1%)/128 49(22.5%)/169 <0.0001
HLA-A,-B,-DRB1 match  0/1/2/3/4/5/6§ 69/80/58/13/3/0/0 47/86/53/24/7/0/0 0.0518 
HLA-A match  0/1/2# 141/76/8 123/89/5 0.2466 
HLA-B match  0/1/2^ 170/49/4 161/52/5 0.8235 
HLA-DRB1 match  0/1/2 135(59.2%)/88/5 107(48.4%)/95/19 0.0031 
Positive crossmatch 45 (19.7%) 17 (7.7%) 0.0009 
Post-transplant features    
Main IS regimen  CsA/Tac/other 210/16/2 201/16/4 0.3835 
Treated acute rejection 71 (31.1%) 47 (21.3%) 0.0175 
Treated CMV infection  36 (15.8%) 19 (8.6%) 0.0201 
HCV RNA at 3 months (log10 IU/mL)  7.20 [6.62-7.60] 6.91 [6.38-7.47] 0.0062 
Antiviral treatment after LT 117 (51.3%) 106 (48%) 0.4776 
SVR at 24 weeks 25 (21.4%) 36 (34%) 0.0351 
Numerical variables are expressed as median [Q1-Q3] or mean ± standard deviation according to their 
non-parametric or parametric distribution. Categorical variables are expressed as numbers 
(prevalence, %) 
In bold significant p values 
Graft quality: suboptimal if graft from donor ≥ 65 years and/or with macrovesicular steatosis ≥ 15%, 
according to Salizzoni M et al. Transpl Int 2003 
£23, $15, &81, °6, §9, #7, ^8 missing data 
Abbreviations: CMV, cytomegalovirus; CsA, cyclosporine; D, donor; D-MELD, donor age x recipient 
MELD; HBV, hepatitis B virus; HBV-core Ab, anti-core HBV antibodies; HCC, hepatocellular 
carcinoma; HCV, hepatitis C virus; HLA, human leukocyte antigen; IL28B, Interleukin 28B; IS, 
immunosuppression; LT, liver transplantation; MELD, Model for End-stage Liver Disease; PRA, panel 
reactive antibodies; R, recipient; SVR, sustained virological response; Tac, Tacrolimus 
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TABLE 4. Multivariable analysis output using Cox model in HCV liver transplant recipients 
Covariable  Exp(β) 95% CI 
lower 
95% CI 
upper 
p value 
Recipient HLA-DRB1*11 phenotype 
and IL28B genotype 
baseline value: all other genetic 
combinations 
    
 
at risk: HLA-DRB1*11-negative and 
IL28B non-C/C 
1.74 1.29 2.35 <0.0001 
HCV RNA before LT (IU/mL) baseline value: < 1 x 106     
 
at risk: ≥ 1 x 106 1.45 1.07 1.96 0.017 
MELD at LT baseline value: < 15 
   
0.025 
 
at risk: 15-24 0.95 0.69 1.31 0.756 
 
at risk: ≥ 25 1.74 1.10 2.78 0.019 
Donor IL28B genotype baseline value: non-C/C     
at risk: C/C 1.45 1.08 1.96 0.014 
Donor age (years) baseline value: < 48    0.004 
 
at risk: 48-58 0.86 0.53 1.38 0.517 
 
at risk: 59-69 1.34 0.85 2.09 0.208 
 
at risk: ≥ 70 1.77 1.14 2.74 0.011 
Recipient age (years) baseline value: < 49    0.132 
 
at risk: 49-54 0.73 0.46 1.17 0.191 
 
at risk: 55-59 1.23 0.81 1.87 0.335 
 
at risk: ≥ 60 0.98 0.63 1.52 0.938 
Recipient gender baseline value: male 
    
 
at risk: female 1.36 0.96 1.93 0.082 
Donor HBV-core Ab positive baseline value: negative     
 
at risk: positive 1.41 0.98 2.04 0.067 
Multivariable analysis was performed on 411 cases with fully available data. 
Model Chi-squared = 65.576,  p<0.00001 
In bold significant p values and relevant hazard ratios. 
Abbreviations: HBV, hepatitis B virus; HBV-core Ab, anti-core HBV antibodies; HCV, hepatitis C virus; HLA, human 
leukocyte antigen; IL28B, Interleukin 28B; LT, liver transplantation; MELD, Model for End-stage Liver Disease 
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FIGURE LEGENDS 
 
Figure 1. Identification of patients included in the study. HCV, hepatitis C virus. 
 
Figure 2. Kaplan-Meier curves for liver graft survival in HCV-infected recipients. 
Panel A: stratification by HLA-DRB1*11 phenotype (positive vs. negative). 
Panel B: stratification by IL28B rs12979860 genotype (C/C vs. non-C/C).  
HCV, hepatitis C virus; HLA, human leukocyte antigen; IL28B, Interleukin 28B. 
 
Figure 3. Kaplan-Meier curves for liver graft survival in HCV-negative recipients 
compared with HCV-positive ones divided in two groups according to HLA-DRB1*11 
phenotype and IL28B genotype. 
 Panel A: at 10 years post-transplant. 
 Panel B: at 1 year post-transplant. 
HCV, hepatitis C virus; HLA, human leukocyte antigen; IL28B, Interleukin 28B. 
 
Figure 4. Kaplan-Meier curves for liver graft survival in HCV-infected recipients 
lacking both HLA-DRB1*11 phenotype and IL28B C/C genotype stratified by the 70-
years donor age cutoff.  
Panel A: at 10 years post-transplant. 
Panel B: at 1 year post-transplant. 
HCV, hepatitis C virus; HLA, human leukocyte antigen; IL28B, Interleukin 28B. 
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